Uses of medication: Elotuzumab is used in order to treat multiple myeloma together with the drugs lenalidomide and dexamethasone in patients who have received 1 to 3 prior treatments for their multiple myeloma. It is also used for the treatment of multiple myeloma together with drugs pomalidomide and dexamethasone in adult patients who have given at least 2 prior therapy including lenalidomide and a proteasome inhibitor.
Dosage: The recommended elotuzumab dosage is administered to you by intravenous (IV) infusion into your vein. With lenalidomide and dexamethasone, 10 mg/kg is given intravenously every week for the initial a couple of cycles and every 2 weeks thereafter until the disease progresses or unacceptable toxicity.
Treatment Reactions: The most commonly reported elotuzumab side effects may include:
- Sore throat
- Runny nose
- Upper respiratory tract infection
- Decreased appetite
- Tingling, or burning pain in your arms/legs
Warnings and Precautions
- Patients with empliciti dosing should be monitored for fever as well as other signs of infection and should be treated promptly.
- Patients should be monitored for liver function and stop elotuzumab 400 mg if hepatotoxicity is suspected.
- It is not recommended to mix Empliciti with, or administer as an infusion with, other medicinal products.
- The empliciti 400 mg/300mg may cause infusion reactions. Infusion must be interrupted for Grade-2 or higher infusion reactions and appropriate medical management should be instituted.
- The elotuzumab 300 mg/400mg is administered in together with lenalidomide and dexamethasone. Lenalidomide may be responsible for causing embryo-fetal harm and is contraindicated for use in pregnancy.
- Due to the potential for serious empliciti side effects in breast-fed infants from empliciti administered with lenalidomide/dexamethasone, breastfeeding should be avoided.